News – Jul 12, 2018

Prof. Dr. Kees Hovingh joins Julius Clinical as Scientific Officer

Julius Clinical is pleased to announce that Prof. Kees Hovingh has joined Julius Clinical as Scientific Officer, specialising in Cardiovascular disease, with a sub-speciality in Internal medicine, molecular genetics and atherosclerosis.

“I am very pleased to welcome Kees to Julius Clinical,” stated Rick Grobbee, Chief Scientific Officer. “His experience in cardiovascular disease will significantly enhance the depth of Julius Clinical´s expertise in cardiovascular trials.”

In his research, Prof. Hovingh concentrates on the genesis of cardiovascular diseases and on therapies for patients with cardiovascular ailments, especially disorders of cholesterol metabolism. His main focus is on patients with familial hypercholesterolemia, a hereditary condition characterised by an excessive blood level of LDL cholesterol which leads to premature cardiovascular disease.

Prof. Hovingh is the founder of an international network of specialists treating patients with homozygous Familial Hypercholesterolemia (hoFH), a rare form of FH. These patients sometimes experience a heart attack as early as the age of twenty. Together with colleagues, Prof. Hovingh is evaluating new lipid lowering therapies with his international colleagues.

Prof. Hovingh is an internist in vascular medicine and a staff member of the Department of Vascular Medicine at the AMC. Since 2012, he has been head of the department’s Clinical Trial Unit in Vascular Medicine and since December 2016, vice chair of the Department of Internal Medicine. Hovingh is also a visiting professor at the Imperial College, London.